Indeed, the phosphorylation of Akt in B-CLL and the plasma levels of CXCL13, CCL3, CCL4, and TNFα were found to be significantly reduced in patients treated with CAL-101 (Hoellenriegel et al., 2011; Sharman et al., 2011) suggesting that inhibition of p110δ disrupts the interactions of B-CLL from their protective microenvironment. The gene discussed is CCL4; the disease is B-cell chronic lymphocytic leukemia.